Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Interleukin-13 receptor α2 is associated with poor prognosis in patients with gastric cancer after gastrectomy.

Lin C, Liu H, Zhang H, He H, Li H, Shen Z, Qin J, Qin X, Xu J, Sun Y.

Oncotarget. 2016 Aug 2;7(31):49281-49288. doi: 10.18632/oncotarget.10297.

2.

Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma.

Liu-Chittenden Y, Jain M, Kumar P, Patel D, Aufforth R, Neychev V, Sadowski S, Gara SK, Joshi BH, Cottle-Delisle C, Merkel R, Yang L, Miettinen M, Puri RK, Kebebew E.

Cancer Med. 2015 Jul;4(7):1060-8. doi: 10.1002/cam4.449. Epub 2015 Mar 13.

3.

Autoimmunity as a double agent in tumor killing and cancer promotion.

Toomer KH, Chen Z.

Front Immunol. 2014 Mar 18;5:116. doi: 10.3389/fimmu.2014.00116. eCollection 2014. Review.

4.

IL-13Rα2-bearing, type II NKT cells reactive to sulfatide self-antigen populate the mucosa of ulcerative colitis.

Fuss IJ, Joshi B, Yang Z, Degheidy H, Fichtner-Feigl S, de Souza H, Rieder F, Scaldaferri F, Schirbel A, Scarpa M, West G, Yi C, Xu L, Leland P, Yao M, Mannon P, Puri RK, Fiocchi C, Strober W.

Gut. 2014 Nov;63(11):1728-36. doi: 10.1136/gutjnl-2013-305671. Epub 2014 Feb 10.

5.

The potential for genetically altered microglia to influence glioma treatment.

Li W, Holsinger RM, Kruse CA, Flügel A, Graeber MB.

CNS Neurol Disord Drug Targets. 2013 Sep;12(6):750-62. Review.

6.

Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2.

Balyasnikova IV, Wainwright DA, Solomaha E, Lee G, Han Y, Thaci B, Lesniak MS.

J Biol Chem. 2012 Aug 31;287(36):30215-27. doi: 10.1074/jbc.M112.370015. Epub 2012 Jul 9.

7.

Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.

Jain M, Zhang L, He M, Patterson EE, Nilubol N, Fojo AT, Joshi B, Puri R, Kebebew E.

Cancer. 2012 Nov 15;118(22):5698-708. doi: 10.1002/cncr.27629. Epub 2012 May 8.

8.

Cysteamine suppresses invasion, metastasis and prolongs survival by inhibiting matrix metalloproteinases in a mouse model of human pancreatic cancer.

Fujisawa T, Rubin B, Suzuki A, Patel PS, Gahl WA, Joshi BH, Puri RK.

PLoS One. 2012;7(4):e34437. doi: 10.1371/journal.pone.0034437. Epub 2012 Apr 20.

9.

Galectins in hematological malignancies.

St-Pierre Y.

Am J Blood Res. 2011;1(2):119-29. Epub 2011 Sep 7.

10.

Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment.

Li X, Ma Q, Xu Q, Duan W, Lei J, Wu E.

Curr Pharm Des. 2012;18(17):2404-15. Review.

11.

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW.

Cancer Immunol Immunother. 2011 Oct;60(10):1419-30. doi: 10.1007/s00262-011-1028-0. Epub 2011 Jun 5.

12.

Genomic profiling of genes contributing to metastasis in a mouse model of thyroid follicular carcinoma.

Lu C, Mishra A, Zhu YJ, Meltzer P, Cheng SY.

Am J Cancer Res. 2011 Jan 1;1(1):1-13.

13.
14.

Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation.

Pedroza-Gonzalez A, Xu K, Wu TC, Aspord C, Tindle S, Marches F, Gallegos M, Burton EC, Savino D, Hori T, Tanaka Y, Zurawski S, Zurawski G, Bover L, Liu YJ, Banchereau J, Palucka AK.

J Exp Med. 2011 Mar 14;208(3):479-90. doi: 10.1084/jem.20102131. Epub 2011 Feb 21.

Supplemental Content

Support Center